---
title: "Zevra Denmark A/S — Financial report"
canonical_url: "https://datapublica.dk/en/companies/43259326-zevra-denmark-a-s/financials"
locale: "en"
route_type: "company_financials"
robots: "index,follow"
content_access: "standard"
---

# Zevra Denmark A/S — Financial report

CVR 43259326

## Latest financial period

- 2025 • 2025-01-01 • 2025-12-31 • entity • DKK • 123335000 • 404024000 • 357338000 • 334468000 • 538365000 • 174841000 • 4

## Financial history

- 2024 • 2024-01-01 • 2024-12-31 • entity • DKK • 70973000 • -1728000 • -29053000 • -132114000 • 178169000 • -159627000 • 4

- 2023 • 2023-01-01 • 2023-12-31 • entity • DKK • -12548000 • -28188000 • -20506000 • 189146000 • -27513000 • 6

- 2022 • 2022-01-01 • 2022-12-31 • entity • DKK • -1393000 • -12009000 • -7406000 • 199206000 • -7007000 • 8

- 2022 • 2022-05-13 • 2022-12-31 • entity • DKK • 1671000 • -12009000 • -7406000 • 199206000 • -7006 • 8

## Annual report highlights

- primary activities • Business reviewZevra Denmark A/S \(the Company\) is a subsidiary of Zevra Therapeutics, Inc. \(the parent\), a U.S.based commercial-stage therapeutics company. Zevra Therapeutics, Inc. \(Massachusetts, USA\) became a public traded company on the NASDAQ Stock Exchange as of 7 January 2021.

Zevra Denmark A/S is a therapeutics company focused on bringing life-changing therapeutics to people living with rare diseases. The Company’s main asset includes arimoclomol, an orally delivered product for the treatment of Niemann-Pick disease type C \(NPC\), which has been granted approval as a treatment for NPC by the U.S. Food and Drug Administration \(FDA\) and is commercialized under the brand name MIPLYFFA in the U.S. The Company has licensed the rights to commercialize the drug worldwide to Zevra Therapeutics, Inc.

Following the U.S. approval of MIPLYFFA in September 2024, the Company has transitioned from a development-stage entity to a royalty-generating entity. Under the license agreement entered into with its parent company, the exclusive rights to commercialize MIPLYFFA have been transferred, and the Company is entitled to receive royalty income based on net sales.

MIPLYFFA is currently being commercialized in the United States by Zevra Therapeutics, Inc. following its approval by the FDA as a treatment for NPC.

In Europe, arimoclomol has received orphan medicinal product designation from the European Medicines Agency \(EMA\), and a Marketing Authorization Application \(MAA\) has been submitted. The product is currently under regulatory review. Patients may access the treatment through expanded access programs in certain countries pending regulatory approval • entity

- development in activities and financial affairs • Financial review The Company's income statement for the year ended 31 December 2025 shows a positive result of kDKK 334.468, and the balance sheet at 31 December 2025 shows equity of kDKK 174.842. The result for the year is positively impacted by the other operating income of kDKK 320.242 relating to the recognition of income from transfer of the priority voucher. Reference is made to note 12.Financing and the going concern assumptionAs of 31 December 2025, the Company reports positive equity, and total current assets exceed total current liabilities. Based on the Company’s current financial position and expected level of activity for the foreseeable future, Management expects the Company to be able to meet its obligations as they fall due at least through 31 December 2026. The Company continues to have access to financial support from its parent company, Zevra Therapeutics, Inc., if required. Accordingly, Management and the Board of Directors have prepared the financial statements on a going concern basis. • entity

- going concern uncertainty • As of 31 December 2025, the Company reports positive equity, and total current assets exceed total current liabilities. Based on the Company's current financial position and expected level of activity for the foreseeable future, Management expects the Company to be able to meet its obligations as they fall due at least through 31 December 2026. The Company continues to have access to financial support from its parent company, Zevra Therapeutics, Inc., if required. Accordingly, Management and the Board of Directors have prepared the financial statements on a going concern basis • entity

- recognition measurement uncertainty • Recognition and measurement uncertaintiesRecognition and measurement uncertainties exists in respect to the Company's accounting for revenue related discount and rebate liabilities as disclosed further in note 8 and timing for the recognition of income from transfer of intangible rights, and valuation of uncertain tax positions as further disclosed in note 5 and 12. • entity

- subsequent events • Significant events occurring after the end of the financial yearNo events have occurred after the balance sheet date which could significantly affect the Company's financial position. • entity

- subsequent events • After the balance sheet date no major events have occurred which significantly affect the evaluation of the financial statements for 2025. • entity

- contingent liabilities • Contingent liabilities relating to ongoing transfer pricing audit

The Company is subject to an ongoing transfer pricing audit by the Danish tax authorities in relation to the allocation and timing of income arising from inter-company transaction, as disclosed in note 12.

The Company has recognized an uncertain tax position in respect of this matter, as disclosed in note 12, reflecting management’s best estimate of the expected outcome based on available information. TThe uncertain tax position reflects management's best estimate of the expected outcome, including probability-weighted consideration of penalties, interest and other related exposures.

While management considers the recognized amount to be appropriate, the ultimate outcome of the audit remains uncertain and may differ from the amount currently recognized.Other contingent liabilities not recognised in balance sheetAs security for bank withdrawals, the Company has pledge bank accounts with total value of DKK 500 thousand. • entity